1
CSOWM Questions and Answers | Already
passed | Latest Update
Management of BMI >/= 25
🗸🗸: Diet, Exercise, Behavior
Management of BMI >/=30
🗸🗸: Diet, exercise, behavior + pharmacotherapy
Management of BMI >/= 27 + comorbidity
🗸🗸: Diet, exercise, behavior + pharmacotherapy
Management of BMI >/=35 + cormorbidity
🗸🗸: Bariatric surgery
Management of BMI >/=40
🗸🗸: Bariatric surgery
, 2
Co-morbidities
🗸🗸: T2DM
HTN
OSA and other respiratory disorders
NAFLD
OA
lipid abnormalities
gastrointestinal disorders
heart disease
Medication assessment
🗸🗸: Every month x3 months, then every 3 months
Effective weight loss %
🗸🗸: >/=5% in 3 months
Avoid these wt loss meds with HTN/HD
🗸🗸: Sympathomimetics (phentermine/diethylproprion)
Avoid these wt loss medications with CVD
, 3
🗸🗸: Sypathomimetics
T2DM treatment + medications to support weight loss
🗸🗸: GLP-1 analog (mitigates associated weight gain due to insulin) or SGLT-2 inhibitors +
metformin. If using insulin, recommend basal instead of combo
Drugs that induce weight gain
🗸🗸: Tricyclic antidepressants (Amitriptyline)
oral contraceptives (Ortho Tri-Cyclen, Yaz)
antipsychotics (Risperidone)
anticonvulsants
glucocorticoids (cortisol)
sulfonyureas- ( Glimepiride, Glipizide)
glitazones (Actos)
B-blockers (Propranolol, Metoprolol, Atenolol)
Hormonal signals for appetite
🗸🗸: CCK- duodenum
K cells- duodenum and jejunum: gatric inhibitory polypeptide
PYY- ileum and colon
, 4
GLP-1 -ileum
Pancreas- Insulin
Adipose tissue: Leptin
Liver- glucagon
GLP-1
🗸🗸: Secreted in response to glucose and promotes insulin release from pancreas and satiety
Ghrelin
🗸🗸: produced in the stomach, orexigenic
Leptin
🗸🗸: proportional to fat mass, anorexigenic
Inhibits appetite
PYY
CSOWM Questions and Answers | Already
passed | Latest Update
Management of BMI >/= 25
🗸🗸: Diet, Exercise, Behavior
Management of BMI >/=30
🗸🗸: Diet, exercise, behavior + pharmacotherapy
Management of BMI >/= 27 + comorbidity
🗸🗸: Diet, exercise, behavior + pharmacotherapy
Management of BMI >/=35 + cormorbidity
🗸🗸: Bariatric surgery
Management of BMI >/=40
🗸🗸: Bariatric surgery
, 2
Co-morbidities
🗸🗸: T2DM
HTN
OSA and other respiratory disorders
NAFLD
OA
lipid abnormalities
gastrointestinal disorders
heart disease
Medication assessment
🗸🗸: Every month x3 months, then every 3 months
Effective weight loss %
🗸🗸: >/=5% in 3 months
Avoid these wt loss meds with HTN/HD
🗸🗸: Sympathomimetics (phentermine/diethylproprion)
Avoid these wt loss medications with CVD
, 3
🗸🗸: Sypathomimetics
T2DM treatment + medications to support weight loss
🗸🗸: GLP-1 analog (mitigates associated weight gain due to insulin) or SGLT-2 inhibitors +
metformin. If using insulin, recommend basal instead of combo
Drugs that induce weight gain
🗸🗸: Tricyclic antidepressants (Amitriptyline)
oral contraceptives (Ortho Tri-Cyclen, Yaz)
antipsychotics (Risperidone)
anticonvulsants
glucocorticoids (cortisol)
sulfonyureas- ( Glimepiride, Glipizide)
glitazones (Actos)
B-blockers (Propranolol, Metoprolol, Atenolol)
Hormonal signals for appetite
🗸🗸: CCK- duodenum
K cells- duodenum and jejunum: gatric inhibitory polypeptide
PYY- ileum and colon
, 4
GLP-1 -ileum
Pancreas- Insulin
Adipose tissue: Leptin
Liver- glucagon
GLP-1
🗸🗸: Secreted in response to glucose and promotes insulin release from pancreas and satiety
Ghrelin
🗸🗸: produced in the stomach, orexigenic
Leptin
🗸🗸: proportional to fat mass, anorexigenic
Inhibits appetite
PYY
